IX Biopharma - Stock Analyst Research

Target Price* 0.250
Recommendation BUY
Market Cap*-
Publication Date3 Oct 2022

*At the time of publication

iX Biopharma Ltd - Journey taking longer but progressing

  • Annuity stream from milestone and royalty payments of Wafermine is on track, with out-licensing partner Seelos Therapeutics (SEEL US, Non-Rated) planning Phase 2 trials for Complex Regional Pain Syndrome (CRPS) in 2QFY23.
  • iX Biopharma has expanded its pipeline of drugs by developing a sublingual wafer containing dexmedetomidine to treat multiple indications including Alzheimer’s disease-related agitation.
  • Near-term developments include expanding markets for the distribution of cannabis to the United Kingdom and United States. We expect FY23e revenue from Xativa and nutraceuticals. We lowered our DCF target price to S$0.25 (prev. S$0.355) due to the delays in capacity expansion and drug trials, and have nudged up our WACC assumption. iX Biopharma is re-purposing active ingredients into higher efficacy drugs using its sublingual Waferix. Targeted treatments include acute pain, CRPS, acute agitation in dementia, male erectile dysfunction, vaccine delivery and medicinal cannabis.

 

PHARMACEUTICALS

  1. Wafermine: treatment of CRPS
  • In the licensing agreement with Seelos in November 2021, iX Biopharma received US$4.7mn in cash and 2.57mn in Seelos shares. Around 0.3mn Seelos shares were paid as fees. The company retains 2.27mn shares on the balance sheet valued at S$2.3mn. There was a S$3.2mn fair value loss due to the decline in the share price. These shares are now valued at around S$3.4mn.
  • The company was granted US FDA orphan designation for CRPS, a rare disorder. Following the out-licensing to Seelos, Seelos is planning to begin Phase 2 trials for CRPS in 2QFY23. Seelos has designated the drug as SLS-003. It is expected that Seelos will have market exclusivity of seven years from regulatory approval of the drug.
  • Seelos will make payments up to US$239mn upon the achievement of certain development and sales milestones together with royalties on future sales. All costs including development and registration of the product will be borne by Seelos.

 

  1. Dexmedetomidine: treatment of agitation in dementia
  • iX Biopharma is developing a sublingual dexmedetomidine wafer for the treatment of agitation in dementia. Dexmedetomidine was initially approved as an intravenous infusion (IV) by the US Food and Drug Administration (FDA) as a sedative medication.
  • Drug formulation has been completed and Phase 1 human study is underway with results in December 2022/January 2023

 

  1. Wafesil: treatment of male erectile dysfunction
  • In September 2021, a supply agreement was signed with China Resources Pharmaceutical Commercial Group Co., Ltd (CRPCG). CRPCG is responsible for obtaining the marketing authorisation for Wafesil in China. There will be upfront and licensing fee payments prior to the commercialisation of Wafesil. We expect filling with the Chinese regulators to be conducted by 1Q23.
  • iX Biopharma is also looking at the distribution of Wafesil in other countries.

 

  1. Xativa: sublingual medicinal cannabis
  • Xativa, the company’s sublingual Cannabidiol (CBD) wafer is sold in in Australia with a prescription in a variety of dosage strengths. We expect more product enhancements including combining with other nutraceutical ingredients. The company will be introducing a Tetrahydrocannabinol (THC) only version (called Hypera) in 2Q23.
  • The company plans to market Xativa in larger cannabis markets outside Australia including the UK and US. Regulatory approval in the UK is progressing although it was delayed due to the pandemic

 

NUTRACEUTICALS

The Entity nutraceutical is sold in China through Tmall Global and JD Worldwide.The lockdowns and tight border controls affected delivery time and cost. Products had to be COVID-19 tested before arrival in China. To differentiate its nutraceuticals, iX does 3rd party clinical trials for the efficacy of its products. Positive results will be supportive of their marketing efforts.

 

CAPACITY

Capacity has been boosted six times with new freeze dry equipment in Australia. The effective increase in capacity was in 4QFY22.

 

 

Recommendation

Our DCF model is highly dependent on development milestone payments and sales royalties from Wafermine. There is a high level of uncertainty over these cash-flows as it assumes completion of drug trials and successful sales of Wafermine.

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com